Market Place
Sourcing Support
Melinta Therapeutics Partners with BARDA to Advance Two FDA-Approved Antibiotics
10 Jul 2023 //
BUSINESSWIRE
Menarini Group announces a commercial agreement for Vabomere, Orbactiv & Minocin
11 Oct 2018 //
PR NEWSWIRE
Menarini Group announces a commercial agreement for Vabomere, Orbactiv & Minocin
11 Oct 2018 //
PR NEWSWIRE
Commonly used antibiotic in India under USFDA lens
13 Jul 2018 //
ECONOMIC TIMES
FDA warning for fluoroquinolone antibiotics on risks of adverse reactions
11 Jul 2018 //
PHARMABIZ
Melinta Publication Highlights Baxdela Activity Against Fluoroquinolone
25 Jun 2018 //
PRESS RELEASE
Melinta Therapeutics Announces Closing of Underwritten Public Offering
29 May 2018 //
PRESS RELEASE
Melinta Partner, Menarini Group, Submits MAA for Delafloxacin in Europe
13 May 2018 //
PRESS RELEASE
Melinta to Highlight Commitment to Antibiotics and Product Portfolio
08 Mar 2018 //
PRESS RELEASE
Melinta Commercial Partner Eurofarma Submit MAA for Delafloxacin in Argentina
20 Feb 2018 //
PRESS RELEASE
Melinta Therapeutics Launches Antibiotic Baxdela™ (delafloxacin) in the US
29 Jan 2018 //
PRESS RELEASE
Melinta Completes Acquisition of The Medicines Company’s
08 Jan 2018 //
PRESS RELEASE
In latest deal, Melinta $270M pact to buy out Medicines Co’s infectious disease
30 Nov 2017 //
ENDPTS
Melinta Announces Successful Completion of Merger
06 Nov 2017 //
PRESS RELEASE
Melinta Presenting Detailed Analyses from Baxdela Phase 3 ABSSSI Trials
25 Sep 2017 //
PRESS RELEASE
ScinoPharm showcases water treatment tech at Baxdela API plant
17 Aug 2017 //
IN PHARMATECHNOLOGIST
Melinta will beef up its antibiotics pipeline, merger with troubled Cempra
09 Aug 2017 //
ENDPTS
Melinta Announces U.S. FDA Approval of Baxdela™ (Delafloxacin) (ABSSSI)
19 Jun 2017 //
PRESS RELEASE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.